Lixisenatide Reduced Damage in Hippocampus CA1 Neurons in a Rat Model of Cerebral Ischemia-Reperfusion Possibly Via the ERK/P38 Signaling Pathway
The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) is a gut-derived peptide that has various physiological actions. One of its main actions is the regulation of blood glucose level when it is elevated as it potentiates insulin release. It is also known that GLP-1 protects neurons from damage caused by neurodegenerative diseases. Lixisenatide is one of the GLP-1 analogues that has a strong affinity to the GLP-1 receptor. Experimental animal studies have shown that it holds a neuroprotective effect in Parkinson, myocardial, and cerebral ischemic disease animal models. The beneficial effect of lixisenatide on the brain after cerebral ischemia-reperfusion (I/R) is not clarified yet; thus, it needs further explanatory studies. Our research is the first to study the effect of lixisenatide on myeloperoxidase (MPO) and toll-like receptors (TLRs)/mitogen-activated protein kinase (MAPK) pathway in a rat model of cerebral I/R. Lixisenatide with 2 doses 0.7 and 7 nmol/kg was given intraperitoneal in 2 different groups for 14 days; then, the bilateral common carotid artery was occluded for 1 h followed by reperfusion for 1 h. Examination of hippocampus CA1 neurons by Nissl stain showed that the number of intact neurons was elevated in the lixisenatide-treated group related to the control group (I/R group). Lixisenatide exhibited neuroprotection action possibly via downregulation of MPO, TLR2/4, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and pP38 and upregulation of phosphorylated extracellular signal-regulated kinase (pERK1/2); thus, this study gives possible link between lixisenatide and TLR/MAPK pathway following cerebral I/R and supports the use of lixisenatide for neuroprotection against stroke.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In rodent models, lixisenatide, liraglutide, and exenatide have been reported to significantly reduce brain levels of the pro-inflammatory cytokine, tumor necrosis factor α (TNF-α) [71–73].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [73]
In the citing paper
“Reduction of other inflammatory biomarkers has also been reported following GLP-1RA treatment in rodent models of cerebral ischemia, namely myeloperoxidase, IL-1β, IL-6, IL-18, and cyclooxygenase-2 (COX-2), the latter through increasing expression of islet-brain-1 (IB1) [72–74].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [73]
Citations
Cites
2 retracted
Guo, N.-F., Cao, Y.-J., Chen, X., Zhang, Y., Fan, Y.-P., Liu, J. Y. H., & Chen, X.-L. (2019) · PubMed · doi:10.26355/eurrev_201905_17832 · Cited by 15 · cited 1×
“This finding is in agreement with previous studies (Guo et al. 2019; Zhao et al. 2019).”
ResultRetractedZhao, Q., Xu, H., Zhang, L., Liu, L., & Wang, L. (2019) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2019.1620248 · Cited by 14 · cited 1×
“This finding is in agreement with previous studies (Guo et al. 2019; Zhao et al. 2019).”
ResultRetractedEllman, G. L. (1959) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(59)90090-6 · Cited by 26,311 · cited 1×
“No. k739-100) respectively (Ellman 1959; McCord and Fridovich 1969; Mihara and Uchiyama 1978).”
BackgroundMcCord, J. M., & Fridovich, I. (1969) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)63504-5 · Cited by 12,952 · cited 1×
“No. k739-100) respectively (Ellman 1959; McCord and Fridovich 1969; Mihara and Uchiyama 1978).”
BackgroundHeart Disease and Stroke Statistics—2019 Update: A Report From the American Heart Association
Benjamin, E. J., Muntner, P., Alonso, A., Bittencourt, M. S., Callaway, C. W., Carson, A. P., Chamberlain, A. M., Chang, A. R., Cheng, S., Das, S. R., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000659 · Cited by 9,036 · cited 1×
“In 2016, around 80 million persons around the world were affected by stroke in which the majority of 67 million patients were affected by ischemic stroke (Benjamin et al. 2019).”
BackgroundNF-κB signaling in inflammation
Liu, T., Zhang, L., Joo, D., & Sun, S.-C. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.23 · Cited by 8,791 · cited 11×
“Activation of TGF-β-activated kinase 1 (TAK-1) leads to activation of P38 and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) which controls the production of proinflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin-1β (IL-1β) (Liu et al. 2017).”
BackgroundInfluentialThrombolysis with Alteplase 3 to 4.5 Hours after Acute Ischemic Stroke
Hacke, W., Kaste, M., Bluhmki, E., Brozman, M., Dávalos, A., Guidetti, D., Larrue, V., Lees, K. R., Medeghri, Z., Machnig, T., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804656 · Cited by 6,684 · cited 1×
“Unfortunately, alteplase is efficient only in the first four and half hours following a stroke; thus, further researches should be done to find more useful alternatives (Hacke et al. 2008).”
BackgroundInfluentialDetermination of malonaldehyde precursor in tissues by thiobarbituric acid test
Uchiyama, M., & Mihara, M. (1978) · Analytical Biochemistry · doi:10.1016/0003-2697(78)90342-1 · Cited by 5,188
NF-κB: a key role in inflammatory diseases
Tak, P. P., & Firestein, G. S. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11830 · Cited by 3,918 · cited 1×
“It remains inactivated in the cytoplasm until its inhibitor of kappa B alpha (IκBα) is phosphorylated (Tak and Firestein 2001).”
BackgroundSterile inflammation: sensing and reacting to damage
Chen, G. Y., & Nuñez, G. (2010) · Nature Reviews Immunology · doi:10.1038/nri2873 · Cited by 3,051 · cited 1×
“…Pharmacology and Toxicology Department, Faculty of Pharmacy, Helwan University, Cairo 11795, Egypt associated molecular patterns (DAMPs) which stimulate innate and adaptive immunity by attaching to toll-like receptors (TLRs) (Chen and Nunez 2010; Gulke et al. 2018; Pasare and Medzhitov 2004).”
BackgroundIschemic Cell Death in Brain Neurons
Lipton, P. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1431 · Cited by 3,043 · cited 1×
“Initially, ATP-dependent pumps stop due to ATP reduction; then, sodium increases inside the neurons and depolarization occurs (Lipton 1999).”
BackgroundSt-Pierre, J., Drori, S., Uldry, M., Silvaggi, J. M., Rhee, J., Jäger, S., Handschin, C., Zheng, K., Lin, J., Yang, W., et al. (2006) · Cell · doi:10.1016/j.cell.2006.09.024 · Cited by 2,233
The Science of Stroke: Mechanisms in Search of Treatments
Moskowitz, M. A., Lo, E. H., & Iadecola, C. (2010) · Neuron · doi:10.1016/j.neuron.2010.07.002 · Cited by 1,930
The inflammatory response in stroke
Wang, Q., Tang, X. N., & Yenari, M. A. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.014 · Cited by 1,177 · cited 1×
“In addition to the oxidative stress, inflammation also plays a pivotal role in damaging neurons after cerebral ischemia (Wang et al. 2007).”
BackgroundTetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia
Yrjänheikki, J., Keinänen, R., Pellikka, M., Hökfelt, T., & Koistinaho, J. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15769 · Cited by 1,006 · cited 1×
“Nissl stain was done for counting intact neurons (Yrjänheikki et al. 1998).”
MethodMolecular mechanisms of calcium-dependent neurodegeneration in excitotoxicity
Arundine, M., & Tymianski, M. (2003) · Cell Calcium · doi:10.1016/s0143-4160(03)00141-6 · Cited by 820 · cited 1×
“Then, the accumulation of calcium in mitochondria triggers proteases and endonuclease enzymes ending up with cell lysis (Arundine and Tymianski 2003).”
BackgroundOxidative Stress in Brain Ischemia
Love, S. (1999) · Brain Pathology · doi:10.1111/j.1750-3639.1999.tb00214.x · Cited by 685 · cited 1×
“Mitochondrial dysfunction, increasing the production of ROS, and inflammation are considered the most important ones (Amantea et al. 2009; Bakthavachalam and Shanmugam 2017; Love 1999).”
BackgroundStructure and Function of Toll Receptors and Their Ligands
Gay, N. J., & Gangloff, M. (2007) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.76.060305.151318 · Cited by 667 · cited 1×
“TLRs are considered pattern recognition receptors composed of 3 domains (Gay and Gangloff 2007).”
BackgroundTissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor
Bullock, B. P., Heller, R. S., & Habener, J. F. (1996) · Endocrinology · doi:10.1210/en.137.7.2968 · Cited by 618 · cited 1×
“Previous studies found that glucagon-like peptide-1 (GLP1) has a neuroprotective property in different types of neurodegenerative diseases (Bullock et al. 1996; Holscher 2012).”
BackgroundEvaluation of Drug Activities: Pharmacometrics
Després, L., & Bacharach, A. L. (1964) · Cited by 465
Post‐ischemic brain damage: pathophysiology and role of inflammatory mediators
Amantea, D., Nappi, G., Bernardi, G., Bagetta, G., & Corasaniti, M. T. (2009) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06766.x · Cited by 459 · cited 1×
“Mitochondrial dysfunction, increasing the production of ROS, and inflammation are considered the most important ones (Amantea et al. 2009; Bakthavachalam and Shanmugam 2017; Love 1999).”
BackgroundToll-like receptors: linking innate and adaptive immunity
Pasare, C., & Medzhitov, R. (2004) · Microbes and Infection · doi:10.1016/j.micinf.2004.08.018 · Cited by 453
Reperfusion injury following cerebral ischemia: pathophysiology, MR imaging, and potential therapies
Pan, J., Konstas, A.-A., Bateman, B., Ortolano, G. A., & Pile-Spellman, J. (2007) · Neuroradiology · doi:10.1007/s00234-006-0183-z · Cited by 390 · cited 1×
“In addition to ischemic damage, reperfusion was also found to cause harm in damaging brain cells (Pan et al. 2007).”
BackgroundNF-κB signaling in cerebral ischemia
Ridder, D. A., & Schwaninger, M. (2009) · Neuroscience · doi:10.1016/j.neuroscience.2008.07.007 · Cited by 386 · cited 11×
“Activation of TGF-β-activated kinase 1 (TAK-1) leads to activation of P38 and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) which controls the production of proinflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin-1β (IL-1β) (Liu et al. 2017).”
InfluentialMitochondrial and apoptotic neuronal death signaling pathways in cerebral ischemia
Niizuma, K., Yoshioka, H., Chen, H., Kim, G. S., Jung, J. E., Katsu, M., Okami, N., & Chan, P. H. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.09.002 · Cited by 362 · cited 1×
“Mitochondria participate significantly in destroying the brain through the production of large amounts of reactive oxygen species (ROS) which in turn will exceed the capacity of antioxidant enzymes such as superoxide dismutase (SOD) and catalase (Niizuma et al. 2010).”
BackgroundDanger signals in stroke and their role on microglia activation after ischemia
Gülke, E., Gelderblom, M., & Magnus, T. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418774254 · Cited by 321
Liu, W., Jalewa, J., Sharma, M., Li, G., Li, L., & Hölscher, C. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.054 · Cited by 246 · cited 2×
“Experimental animal studies showed that Lixi has a neuroprotective effect when studied in Parkinson, Alzheimer, myocardial, and cerebral ischemic disease animal models (AbdelLatif et al. 2018a, b; Cai et al. 2018; Liu et al. 2015; Wohlfart et al. 2013).”
BackgroundMethodDual roles of the MAPK/ERK1/2 cell signaling pathway after stroke
Sawe, N., Steinberg, G., & Zhao, H. (2008) · Journal of Neuroscience Research · doi:10.1002/jnr.21604 · Cited by 238 · cited 1×
“It may be either useful or detrimental to neurons (Sawe et al. 2008).”
BackgroundHamilton, A., & Hölscher, C. (2009) · NeuroReport · doi:10.1097/wnr.0b013e32832fbf14 · Cited by 227 · cited 1×
“This is due to the presence of GLP-1 receptors in the hippocampus and cerebral cortex and other areas in the brain (Hamilton and Holscher 2009).”
BackgroundGlucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
Grieco, M., Giorgi, A., Gentile, M. C., d’Erme, M., Morano, S., Maras, B., & Filardi, T. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01112 · Cited by 218 · cited 1×
“GLP-1 analogues such as exenatide and liraglutide showed anti-inflammatory and antiapoptotic effects when tried in neurodegenerative diseases and cerebral ischemic models (Grieco et al. 2019; Sato et al. 2013; Wicinski et al. 2019).”
BackgroundMitogen-Activated Protein Kinases and Cerebral Ischemia
Nozaki, K., Nishimura, M., & Hashimoto, N. (2001) · Molecular Neurobiology · doi:10.1385/mn:23:1:01 · Cited by 205 · cited 4×
“The hippocampus CA1 pyramidal neurons are the most affected cells in the brain after stroke (Nozaki et al. 2001).”
BackgroundInfluentialPotential Role of Glucagon-Like Peptide-1 (GLP-1) in Neuroprotection
Hölscher, C. (2012) · CNS Drugs · doi:10.2165/11635890-000000000-00000 · Cited by 191 · cited 1×
“Previous studies found that glucagon-like peptide-1 (GLP1) has a neuroprotective property in different types of neurodegenerative diseases (Bullock et al. 1996; Holscher 2012).”
BackgroundWerner, U., Haschke, G., Herling, A. W., & Kramer, W. (2010) · Regulatory Peptides · doi:10.1016/j.regpep.2010.05.008 · Cited by 173 · cited 10×
“Previous studies showed that the anti-inflammatory properties of Lixi in cerebral I/R models are independent on GLP-1 receptor because its effect against inflammation remains present even after using GLP-1 receptor antagonist (exendin (9-39)) (Abdel-Latif et al. 2018a).”
BackgroundInfluentialMcClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.07.015 · Cited by 170 · cited 1×
“The dose of Lixi was selected and converted from mouse to rat depending on the previous literature (Laurence and Bacharach 1964; Liu et al. 2015; McClean and Holscher 2014).”
MethodJiang, M., Li, J., Peng, Q., Liu, Y., Liu, W., Luo, C., Peng, J., Li, J., Yung, K. K. L., & Mo, Z. (2014) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0167-6 · Cited by 160
TLR2 and TLR4 in the Brain Injury Caused by Cerebral Ischemia and Reperfusion
Wang, Y., Ge, P., & Zhu, Y. (2013) · Mediators of Inflammation · doi:10.1155/2013/124614 · Cited by 144 · cited 3×
“Bax, Bcl-2associated x; Bcl2, B cell lymphoma 2; DAMPs, damage-associated molecular patterns; ERK, extracellular signal–regulated kinase; GLP-1R, glucagon-like peptide-1 receptor; IRAK, interleukin-1 receptor– associated kinase; I/R, ischemia/reperfusion; IL-1β, interleukin-1β; IKK-β, inhibitor of nuclear factor kappa…”
BackgroundPiao, C. S., Kim, J., Han, P., & Lee, J. (2003) · Journal of Neuroscience Research · doi:10.1002/jnr.10671 · Cited by 123 · cited 11×
“Activation of TGF-β-activated kinase 1 (TAK-1) leads to activation of P38 and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) which controls the production of proinflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin-1β (IL-1β) (Liu et al. 2017).”
BackgroundInfluentialPeroval, M. Y., Boyd, A. C., Young, J. R., & Smith, A. L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0051243 · Cited by 121 · cited 1×
“The other downstream signaling pathway of TLR is MAPK (Gesuete et al. 2014; Peroval et al. 2013).”
BackgroundNeuroprotective Effects of Liraglutide for Stroke Model of Rats
Sato, K., Kameda, M., Yasuhara, T., Agari, T., Baba, T., Wang, F., Shinko, A., Wakamori, T., Toyoshima, A., Takeuchi, H., et al. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141121513 · Cited by 120 · cited 1×
“GLP-1 analogues such as exenatide and liraglutide showed anti-inflammatory and antiapoptotic effects when tried in neurodegenerative diseases and cerebral ischemic models (Grieco et al. 2019; Sato et al. 2013; Wicinski et al. 2019).”
BackgroundMitochondrial dysfunction – Silent killer in cerebral ischemia
Pramila, B., & Shanmugam, P. S. T. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.02.043 · Cited by 119 · cited 1×
“Mitochondrial dysfunction, increasing the production of ROS, and inflammation are considered the most important ones (Amantea et al. 2009; Bakthavachalam and Shanmugam 2017; Love 1999).”
BackgroundToll-Like Receptors and Ischemic Brain Injury
Gesuete, R., Kohama, S. G., & Stenzel-Poore, M. P. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000068 · Cited by 117 · cited 9×
“Upregulation of these receptors occurred because of DAMPs that are released from necrotic brain tissues and causes activation of TLR2/4 (Gesuete et al. 2014).”
BackgroundInfluentialCai, H.-Y., Yang, J.-T., Wang, Z.-J., Zhang, J., Yang, W., Wu, M.-N., & Qi, J.-S. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.114 · Cited by 108 · cited 14×
“Activation of TGF-β-activated kinase 1 (TAK-1) leads to activation of P38 and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) which controls the production of proinflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin-1β (IL-1β) (Liu et al. 2017).”
BackgroundResultInfluentialCui, L., Zhang, X., Yang, R., Liu, L., Wang, L., Li, M., & Du, W. (2010) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2010.07.007 · Cited by 95 · cited 1×
“This finding was in agreement with other studies and suggested that the neuroprotection of Lixi may be due to its inhibitory effect on P38 (Cai et al. 2018; Cui et al. 2010).”
ResultBaicalin Inhibits TLR2/4 Signaling Pathway in Rat Brain Following Permanent Cerebral Ischemia
Tu, X.-K., Yang, W.-Z., Shi, S., Chen, Y., Wang, C.-H., Chen, C., & Chen, Z. (2010) · Inflammation · doi:10.1007/s10753-010-9254-8 · Cited by 95 · cited 1×
“Many researches proved that downregulation ofNF-κB is associatedwith neuroprotection (Dong et al. 2013; Tu et al. 2011).”
BackgroundWiciński, M., Socha, M., Malinowski, B., Wódkiewicz, E., Walczak, M., Górski, K., Słupski, M., & Pawlak-Osińska, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20051050 · Cited by 89 · cited 2×
“GLP-1 analogues such as exenatide and liraglutide showed anti-inflammatory and antiapoptotic effects when tried in neurodegenerative diseases and cerebral ischemic models (Grieco et al. 2019; Sato et al. 2013; Wicinski et al. 2019).”
BackgroundGLP-1 receptor agonists show neuroprotective effects in animal models of diabetes
Gault, V. A., & Hölscher, C. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.017 · Cited by 86 · cited 1×
“Previous researches proved that GLP-1 receptor agonist has neuroprotection effect (Gault and Holscher 2018).”
BackgroundSeif-El-Nasr, M., & ABDELFATTAH, A. (1995) · Pharmacological Research · doi:10.1016/s1043-6618(05)80014-3 · Cited by 81 · cited 1×
“Following 1 h, the knot in both arteries was released and the skin was sutured (Seif-El-Nasr and El-Fattah 1995; Ulrich et al. 1998).”
MethodCardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies
Wohlfart, P., Linz, W., Hübschle, T., Linz, D., Huber, J., Hess, S., Crowther, D., Werner, U., & Ruetten, H. (2013) · Journal of Translational Medicine · doi:10.1186/1479-5876-11-84 · Cited by 78 · cited 1×
“Experimental animal studies showed that Lixi has a neuroprotective effect when studied in Parkinson, Alzheimer, myocardial, and cerebral ischemic disease animal models (AbdelLatif et al. 2018a, b; Cai et al. 2018; Liu et al. 2015; Wohlfart et al. 2013).”
BackgroundHuang, H., Zhong, R., Xia, Z., Song, J., & Feng, L. (2014) · Molecules · doi:10.3390/molecules190811196 · Cited by 77
Dong, L., Qiao, H., Zhang, X., Zhang, X., Wang, C., Wang, L., Cui, L., Zhao, J., Xing, Y., Li, Y., et al. (2013) · Mediators of Inflammation · doi:10.1155/2013/370804 · Cited by 61 · cited 1×
“Many researches proved that downregulation ofNF-κB is associatedwith neuroprotection (Dong et al. 2013; Tu et al. 2011).”
BackgroundHan, D., Wei, J., Zhang, R., Ma, W., Shen, C., Feng, Y., Xia, N., Xu, D., Cai, D., Li, Y., et al. (2016) · Scientific Reports · doi:10.1038/srep35319 · Cited by 61 · cited 1×
“Additionally, occlusion of BCCAwas found to significantly increase the mRNA expression of TLR2/4 which was reported in the previous study (Han et al. 2016; Huang et al. 2014).”
ResultUlrich, P. T., Kroppenstedt, S. N., Heimann, A., & Kempski, O. S. (1998) · Stroke · doi:10.1161/01.str.29.11.2412 · Cited by 60 · cited 1×
“Following 1 h, the knot in both arteries was released and the skin was sutured (Seif-El-Nasr and El-Fattah 1995; Ulrich et al. 1998).”
MethodBeray-Berthat, V., Croci, N., Plotkine, M., & Margaill, I. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03224-4 · Cited by 57
Toll-like receptor-4 and cytokine cascade in stroke after exercise
Zwagerman, N. T., Plumlee, C., Guthikonda, M., & Ding, Y. (2009) · Neurological Research · doi:10.1179/016164109x12464612122812 · Cited by 44 · cited 5×
“Upregulation of these receptors occurred because of DAMPs that are released from necrotic brain tissues and causes activation of TLR2/4 (Gesuete et al. 2014).”
BackgroundInfluentialAbdellatif, R., Heeba, G. H., Taye, A., & Khalifa, M. M. A. (2018) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-018-1497-1 · Cited by 41
Zhao, Z., & Pu, Y. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.11.135 · Cited by 37
Winters, L., Winters, T., Gorup, D., Mitrečić, D., Čurlin, M., Križ, J., & Gajović, S. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.02.001 · Cited by 32 · cited 5×
“Upregulation of these receptors occurred because of DAMPs that are released from necrotic brain tissues and causes activation of TLR2/4 (Gesuete et al. 2014).”
BackgroundInfluentialGenetic neutrophil deficiency ameliorates cerebral ischemia-reperfusion injury
Frieler, R. A., Chung, Y., Ahlers, C. G., Gheordunescu, G., Song, J., Vigil, T. M., Shah, Y. M., & Mortensen, R. M. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.08.016 · Cited by 32 · cited 1×
“Neutrophil infiltration plays an important role in damaging of neurons after cerebral ischemia (BerayBerthat et al. 2003; Frieler et al. 2017).”
BackgroundAbdellatif, R., Heeba, G. H., Taye, A., & Khalifa, M. M. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.05.045 · Cited by 28 · cited 2×
“Previous studies showed that the anti-inflammatory properties of Lixi in cerebral I/R models are independent on GLP-1 receptor because its effect against inflammation remains present even after using GLP-1 receptor antagonist (exendin (9-39)) (Abdel-Latif et al. 2018a).”
BackgroundLixisenatide for the treatment of type 2 diabetes
Petersen, A. B., Knop, F. K., & Christensen, M. (2013) · Drugs of Today · doi:10.1358/dot.2013.49.9.2020940 · Cited by 24 · cited 1×
“Lixisenatide (Lixi) is one of the GLP-1 analogues which is characterized by its strong affinity to the GLP-1 receptor (Petersen et al. 2013).”
Background(2001) · doi:10.1002/1098-1128(200103)21:2<129::aid-med1003>3.0.co;2-h · cited 1×
“Activation of P38 participates in the damage of neurons after cerebral I/R (Barone et al. 2001; Jiang et al. 2014).”
Background
Cited by
Vergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01686-3 · Cited by 72
“Expression of cerebral caspase-3, involved in apoptosis, was also consistently reduced by exenatide, liraglutide, lixisenatide, and semaglutide in stroke animal models [73, 85, 87, 92, 93].”
BackgroundGLP-1 programs the neurovascular landscape
Chen, B., Yu, X., HORVATH-DIANO, C., Ortuño, M. J., Tschöp, M. H., Jastreboff, A. M., & Schneeberger, M. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.09.003 · Cited by 62
Yang, X., Qiang, Q., Li, N., Feng, P., Wei, W., & Hölscher, C. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.844697 · Cited by 58
“Moreover, one recent study (119) showed that lixisenatide exerted neuroprotection potentially by downregulating levels of NF-κB, TLR2/4, MPO, and pP38 as well as upregulating expression of pERK1/2.”
BackgroundMaskery, M. P., Holscher, C., Jones, S. P., Price, C. I., Strain, W. D., Watkins, C. L., Werring, D. J., & Emsley, H. C. (2021) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x20952011 · Cited by 51
“Reduced levels of other markers of inflammation, such as myeloperoxidase and interleukin, have also been reported.(30,37,51) One study reported a non-statistically significant reduction in pro-inflammatory markers.”
BackgroundYu, S., Fu, J., Wang, J., Zhao, Y., Liu, B., Wei, J., Yan, X., & Su, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010135 · Cited by 35
“Experimental animal studies have shown that it can protect hippocampus CA1 neurons after cerebral ischemia by downregulating TLR2/4–NFκB signaling and upregulating p38/ERK pathway [119].”
Background
Metadata
- Authors
- Gad, S. N., Nofal, S., Raafat, E. M., & Ahmed, A. A. E.
- Affiliations
- Helwan University (EG)
- Corresponding author
- Gad, Salma N.
- Venue
- Journal of Molecular Neuroscience
- Published
- 2020-02-10
- Volume
- 70
- Issue
- 7
- Pages
- 1026-1037
- ISSN
- 0895-8696 (ISSN-L)
- 1559-1166
- OpenAlex
- W3005611049
- Cited by
- 18
- References
- 61
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 3 · 2021: 2 · 2020: 1
- FWCI
- 0.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Journal of Molecular Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- lixisenatide, GLP-1 receptor agonists, cerebral ischemia-reperfusion injury, neuroprotection, CA1 pyramidal neurons, ERK signaling, p38 MAPK, Toll-like receptors, NF-κB, myeloperoxidase, stroke, carotid artery occlusion
- MeSH terms
- Glucagon-Like Peptide-2 Receptor, Animals, Cerebral Infarction, Injections, Intraperitoneal, Peroxidase, Neurons, Peptides, NF-kappa B, Rats, Wistar, Neuroprotective Agents, Mitogen-Activated Protein Kinase 1, MAP Kinase Signaling System, p38 Mitogen-Activated Protein Kinases, Mitogen-Activated Protein Kinase 3, Toll-Like Receptors, Rats, CA1 Region, Hippocampal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.